title: Premenopause contraception with monthly injectable Mesigyna with special emphasis on serum lipid and bone density patterns.
abstract: This 2-year study compared Mesigyna(R) administered to 49 pre-menopausal women between 38 and 50 years, to 99 women fitted with an IUD (Nova-T). A complete lipoprotein assessment was carried out before treatment and at 6, 12, and 24 months of treatment. A bone densitometry was performed on half of the women, and an endometrial biopsy was taken from half of the Meisgyna group before and at the end of the first and second year. No pregnancy occurred with Mesigyna use while three pregnancies were observed with the IUD. The incidence of bleeding anomalies was higher in the Mesigyna group, with a discontinuation rate for these reasons of 20% versus 4% for IUD (p <0.05). The duration of bleeding days as well as dysmenorrhea were less with Mesigyna. No differences were seen in the pattern of intermenstrual bleeding and spinal bone density between both groups. No patient developed endometrial hyperplasia after treatment, thus endometrial risk seemed not to be increased. Total and LDL cholesterol, and apolipoproteins did not show modifications. A slight decrease in total triglycerides, HDL and HDL(2) cholesterol, and IDL lipoproteins was observed with Mesigyna. The present study appears to be the first using a monthly injectable hormonal contraceptive and monitoring its influence on lipid patterns in premenopausal women. Mesigyna proved to be a highly effective and low risk agent for premenopausal users.
authors.affiliation: First Gynecological Clinic, University of Buenos Aires, Buenos Aires, Argentina.
authors.forename: E
authors.initials: E
authors.lastname: von Kesserü
authors.forename: J J
authors.initials: JJ
authors.lastname: Etchepareborda
authors.forename: R
authors.initials: R
authors.lastname: Wikinski
authors.forename: S
authors.initials: S
authors.lastname: Beier
mesh_terms: D000328:Adult; D001118:Argentina; D001706:Biopsy; D015519:Bone Density; D003271:Contraceptive Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects; D004338:Drug Combinations; D004717:Endometrium / Q000473:pathology; D004958:Estradiol / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D006965:Hyperplasia; D007267:Injections; D007434:Intrauterine Devices; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D009640:Norethindrone / Q000031:analogs & derivatives*; D017060:Patient Satisfaction; D011247:Pregnancy; D017697:Premenopause; D014592:Uterine Hemorrhage / Q000139:chemically induced
chemical_list: D003271:Contraceptive Agents, Female; D004338:Drug Combinations; D008055:Lipids; C418365:estradiol, norethindrone drug combination; D004958:Estradiol; D009640:Norethindrone